For endocrine-metabolic comorbidities qualifying as moderate or severe by CIRS, 41% of KCCC patients had diabetes treated with oral agents or insulin, 10% had dyslipidaemia requiring medication, and 11% had other endocrine-related problems (e.g., thyroid disorders). This evidence concerns the gene INS and thyroid gland disorder.